Navigation Links
Niutang Sucralose Patent Litigation Successfully Concluded
Date:6/1/2009

Tate & Lyle will not appeal ITC decision; Voluntarily dismisses District Court case

BREA, Calif., June 1 /PRNewswire/ -- Changzhou Niutang, one of the largest global manufacturers of sucralose, and its U.S. subsidiary, US Niutang, today announced that Tate & Lyle will not appeal the recent decision made by the U.S. International Trade Commission that decisively rejected Tate & Lyle's infringement allegations against Niutang. In addition, Tate & Lyle has requested a voluntary dismissal of the patent infringement allegations it brought against Niutang in the United States District Court.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090528/CG23830LOGO)

"We are delighted to have all aspects of this litigation successfully concluded, with a complete victory in favor of Niutang," said Licheng Wang Jr., General Manager of Changzhou Niutang. "We will continue to focus our attention on what we do best - providing the highest quality sweeteners and food additives along with outstanding service to our worldwide customers."

Niutang has steadily grown its sucralose customer base, which now spans North America, Central America, South America, Europe and Asia. Niutang is already one of the largest manufacturers of aspartame in the world, and it has built upon that successful track record in growing its sucralose business.

"Niutang's sucralose sales have more than tripled from 2007 to 2008," continued Wang. "We recently completed the expansion of our sucralose capacity to 300 metric tons and have announced our plans to increase our capacity to 500 metric tons by 2012. As our sucralose business continues to grow, we remain committed to providing our customers with the high-quality products and unsurpassed level of customer service they have come to expect from Niutang."

Niutang is one of the largest and most experienced global manufacturers of sucralose. The company's established track record is built upon the highest standards of quality control, with products that are:

  • Manufactured according to cGMP requirements as stated in CFR 21 Part 110
  • Produced to meet all quality specifications required by current FCC
  • Moody International ISO 9001:2000/cGMP/HACCP certified
  • Kosher and Halal certified
  • Registered with the U.S. FDA in accordance with the Security and Bioterrorism Preparedness and Response Act of 2002

About Niutang

Niutang Chemical is one of the world's leading manufacturers and distributors of food additives, chemicals and pharmaceutical intermediates that are instrumental to food, beverage, pharmaceutical, nutraceutical and industrial products. Established in 1969, Niutang's commitment to producing the highest quality food additives at competitive prices has ensured its rapid growth into a leading global manufacturer of aspartame, folic acid, and more recently, sucralose. The company is certified in meeting the most stringent U.S. and European manufacturing, compliance and quality benchmarks. Based in China, Niutang also has sales and quality control operations in the United States and Europe that support its strong reputation for integrity and customer service. The company's website is www.niutang.com. For inquiries regarding Niutang Sucralose sales, please contact sales@niutang.us.

    For more information:

    Doreen Lubeck
    DJ Lubeck, LLC
    773-583-4331
    djlubeck@yahoo.com


'/>"/>
SOURCE Niutang Chemical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Niutang to Expand Sucralose Capacity 66 Percent by 2012
2. Niutang Recruits Seasoned Executive to Open U.K. Office
3. GDFII/L&P Sucralose Win Over Competitor Tate & Lyle
4. SENOMYX RECEIVES GENERALLY RECOGNIZED AS SAFE (GRAS) DETERMINATION FOR S2383 SUCRALOSE ENHANCER
5. Falcon Genomics Awarded Patent for Innovative Cancer Test
6. Viral Genetics Has Option Under Issued Key Patent for Cancer Drug
7. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
8. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
9. Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force
10. Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
11. Palomar Wins Two European Hair Removal Patent Opposition Hearings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology: